AstraZeneca Rejects Pfizer's Final Offer - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

AstraZeneca Rejects Pfizer's Final Offer

AstraZeneca’s board of directors rejected Pfizer’s reportedly final offer of $118 billion for a proposed merger of the two companies after a weekend of discussion and offers.

In a statement issued on May 19, Leif Johansson, chairman of AstraZeneca said, said the board rejected Pfizer’s final proposal "because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the company, our employees and the life-sciences sector in the UK, Sweden and the US."

On May 17, AstraZeneca rejected a May 16 offer from Pfizer, stating that the financial terms of the "substantially undervalued the Company and its attractive prospects." The board also asked Pfizer to explain the key aspects of its proposal that were not described in Pfizer’s letter, regarding the business operating model and segmentation which would allow AstraZeneca to deliver on its research and development pipeline and prospects; Pfizer’s plans for cost savings, including around research and development, pipeline delivery and employment; and Pfizer’s proposed tax inversion and regulatory clearances.

Following a conference call between the leaders of the two companies on May 18, the AstraZeneca board rejected the May 16 offer. Later on May 18, Pfizer issued a statement it identified as is final proposal, which the AstraZeneca board rejected on May 19.

In its final offer, Pfizer said that it would not make a hostile takeover offer directlly to AstraZeneca shareholders and would only announce a firm intention to make an offer with the recommendation of the AstraZeneca board.

Under British takeover rules, Pfizer's proposal will expire on May 26. If there is no further discussion or a firm offer, Pfizer must wait six months before making another bid.



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here